^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    RANK ligand inhibitor

    Related drugs:
    Apply
    Denosumab and Nivolumab Combination As 2d-line Therapy in Stage IV NSC Lung Cancer with Bone Metastases (DENIVOS) (NCT03669523)
    Phase 2
    Centre Hospitalier Annecy Genevois
    Completed
    Last update posted :
    02/13/2025
    Initiation :
    11/06/2018
    Primary completion :
    10/19/2023
    Completion :
    10/19/2023
    EGFR • PD-L1 • BRAF • ALK
    |
    PD-L1 expression • EGFR mutation • BRAF mutation • BRAF V600 • ALK translocation
    |
    Opdivo (nivolumab) • Prolia (denosumab) • zoledronic acid
    Studying the Effect of Denosumab on Preventing Breast Cancer in Women With a BRCA1 Germline Mutation (BRCA-P) (NCT04711109)
    Phase 3
    Alliance for Clinical Trials in Oncology
    Recruiting
    Last update posted :
    05/23/2024
    Initiation :
    02/14/2023
    Primary completion :
    07/01/2027
    Completion :
    12/01/2033
    BRCA1 • BRCA
    |
    BRCA mutation
    |
    Prolia (denosumab)
    Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma (NCT03620019)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Completed
    Last update posted :
    04/12/2024
    Initiation :
    09/25/2018
    Primary completion :
    04/15/2023
    Completion :
    08/15/2023
    CD8
    |
    Keytruda (pembrolizumab) • Opdivo (nivolumab) • Prolia (denosumab)
    Observational Study of Bone Complications in People With Post-menopausal Breast Cancer Who Have Stopped Treatment With Denosumab and Aromatase Inhibitors (NCT05590949)
    Phase N/A
    Memorial Sloan Kettering Cancer Center
    Recruiting
    Last update posted :
    12/28/2023
    Initiation :
    10/18/2022
    Primary completion :
    10/18/2024
    Completion :
    10/18/2024
    ALK
    |
    Prolia (denosumab)
    Efficacy of Denosumab on Normal BMD in Women Receiving Adjuvant Aromatase Inhibitors for Early Breast Cancer (NCT03324932)
    Phase 3
    Kyoto Prefectural University of Medicine
    Active, not recruiting
    Last update posted :
    10/06/2023
    Initiation :
    09/25/2017
    Primary completion :
    12/01/2023
    Completion :
    12/01/2027
    ER • PGR
    |
    Prolia (denosumab)
    Study to Determine Treatment Effects of Denosumab in Patients With Breast Cancer Receiving Aromatase Inhibitor Therapy (ABCSG-18) (NCT00556374)
    Phase 3
    Amgen
    Completed
    Last update posted :
    07/27/2023
    Initiation :
    12/18/2006
    Primary completion :
    10/07/2014
    Completion :
    07/26/2022
    ER • PGR
    |
    Prolia (denosumab) • zoledronic acid
    Biomarker Study of the Antitumoral Activity of Denosumab in the Pre- Operative Setting of Early Breast Cancer (D-BIOMARK) (NCT03691311)
    Phase 1
    Institut Català d'Oncologia
    Active, not recruiting
    Last update posted :
    11/03/2021
    Initiation :
    07/05/2018
    Primary completion :
    07/05/2022
    Completion :
    02/05/2023
    HER-2 • ER • CASP3 • TNFSF11
    |
    HER-2 negative
    |
    Prolia (denosumab)
    Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer (NCT01951586)
    Phase 2
    Amgen
    Completed
    Last update posted :
    10/25/2021
    Initiation :
    12/31/2013
    Primary completion :
    07/29/2016
    Completion :
    11/28/2017
    TNFRSF11A • TNFSF11
    |
    cisplatin • carboplatin • Prolia (denosumab) • zoledronic acid
    Denosumab as an add-on Neoadjuvant Treatment (GeparX) (NCT02682693)
    Phase 2
    German Breast Group
    Completed
    Last update posted :
    02/02/2021
    Initiation :
    02/13/2017
    Primary completion :
    12/31/2019
    Completion :
    12/31/2020
    HER-2 • ER • PGR • TNFRSF11A
    |
    HER-2 positive • ER negative
    |
    Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Prolia (denosumab) • cyclophosphamide intravenous
    Presurgical Trial of Denosumab in Breast Cancer (NCT02900469)
    Phase 1
    NYU Langone Health
    Completed
    Last update posted :
    08/21/2020
    Initiation :
    10/01/2016
    Primary completion :
    12/03/2019
    Completion :
    01/03/2020
    TNFSF11
    |
    Prolia (denosumab)
    RANKL Inhibition and Breast Tissue Biomarkers (NCT03629717)
    Phase 1
    Washington University School of Medicine
    Completed
    Last update posted :
    04/14/2020
    Initiation :
    06/01/2018
    Primary completion :
    12/03/2018
    Completion :
    12/03/2018
    TNFRSF11A
    |
    Prolia (denosumab)
    Study to Identify the Impact of Denosumab on the Immune System in Patients With HER2 Negative Breast Cancer (PERIDENO) (NCT03532087)
    Phase 2
    Borstkanker Onderzoek Groep
    Withdrawn
    Last update posted :
    01/18/2020
    Initiation :
    02/01/2018
    Primary completion :
    02/01/2021
    Completion :
    06/01/2023
    HER-2 • IFNG • TNFA • CD4 • TNFSF11
    |
    HER-2 negative
    |
    Prolia (denosumab)
    Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid (NCT02274623)
    Phase 1
    OPKO Health, Inc.
    Completed
    Last update posted :
    09/27/2019
    Initiation :
    12/01/2014
    Primary completion :
    02/27/2017
    Completion :
    03/17/2017
    TAP1
    |
    Prolia (denosumab) • zoledronic acid
    Denosumab in Subjects With Giant Cell Rich Tumors of Bone (NCT03605199)
    Phase 2
    Leiden University Medical Center
    Recruiting
    Last update posted :
    08/26/2019
    Initiation :
    06/18/2018
    Primary completion :
    06/01/2021
    Completion :
    06/01/2023
    GCG
    |
    Prolia (denosumab)
    Breast Cancer Women on Aromatase Inhibitors Treatment (NCT03811509)
    Phase 4
    Parc de Salut Mar
    Recruiting
    Last update posted :
    01/28/2019
    Initiation :
    01/01/2016
    Primary completion :
    01/01/2021
    Completion :
    12/31/2022
    ER
    |
    exemestane • Prolia (denosumab)
    AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer (NCT00089661)
    Phase 3
    Amgen
    Completed
    Last update posted :
    10/17/2018
    Initiation :
    10/01/2004
    Primary completion :
    05/11/2007
    Completion :
    05/27/2009
    ER
    |
    ER positive
    |
    Prolia (denosumab)
    Characteristics and Mechanism of Denosumab-treated Giant Cell Tumor of Bone (NCT03259152)
    Phase 3
    Hebei Medical University Third Hospital
    Unknown status
    Last update posted :
    08/24/2017
    Initiation :
    05/01/2016
    Primary completion :
    05/01/2019
    Completion :
    05/01/2019
    KEAP1 • COL1A1 • GAPDH • ACAN • TNFRSF11B
    |
    Prolia (denosumab)